DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Pivot XB, Bondarenko I, Dvorkin M. et al.
A randomized, double-blind, phase III study comparing SB3 with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
ASCO 2017 Poster 509
Access:
We do not assume any responsibility for the contents of the web pages of other providers.